What is he best known for?
The fields of study he is best known for:
Zhi Zhu focuses on Nanotechnology, Aptamer, DNA, Biophysics and Cancer cell.
Zhi Zhu has included themes like Molecular beacon and Oligonucleotide in his Nanotechnology study.
His work carried out in the field of Aptamer brings together such families of science as Molecule, Photodynamic therapy, Nanomaterials and Photosensitizer.
As a part of the same scientific family, Zhi Zhu mostly works in the field of DNA, focusing on Intracellular and, on occasion, Messenger RNA and Genetic enhancement.
His Biophysics research is multidisciplinary, relying on both Enzymatic amplification, microRNA, Rolling circle replication, Fluorophore and Graphene.
His Cancer cell research incorporates themes from Cell and Molecular biology.
His most cited work include:
- Carbon nanotube-quenched fluorescent oligonucleotides: probes that fluoresce upon hybridization. (458 citations)
- Pyrene-excimer probes based on the hybridization chain reaction for the detection of nucleic acids in complex biological fluids. (418 citations)
- An Aptamer Cross-Linked Hydrogel as a Colorimetric Platform for Visual Detection (268 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Aptamer, Nanotechnology, DNA, Biophysics and Microfluidics.
To a larger extent, Zhi Zhu studies Molecular biology with the aim of understanding Aptamer.
His research is interdisciplinary, bridging the disciplines of Nucleic acid and Nanotechnology.
His DNA research is multidisciplinary, incorporating elements of Combinatorial chemistry and Enzyme.
His biological study spans a wide range of topics, including Molecule, In vivo and Nuclease.
Zhi Zhu interconnects Detection limit, Naked eye and Polyacrylamide in the investigation of issues within Colloidal gold.
He most often published in these fields:
- Aptamer (41.71%)
- Nanotechnology (35.29%)
- DNA (21.93%)
What were the highlights of his more recent work (between 2019-2021)?
- Computational biology (10.70%)
- Aptamer (41.71%)
- Microfluidics (14.44%)
In recent papers he was focusing on the following fields of study:
Zhi Zhu spends much of his time researching Computational biology, Aptamer, Microfluidics, Cell and Nanotechnology.
His Computational biology research is multidisciplinary, incorporating perspectives in Mutation and Nucleic acid.
His Aptamer research incorporates elements of Cancer research, Molecular recognition, Biophysics, PD-L1 and Systematic evolution of ligands by exponential enrichment.
His Microfluidics study integrates concerns from other disciplines, such as Miniaturization and Stimuli responsive.
Zhi Zhu combines subjects such as RNA and Cellular differentiation with his study of Cell.
Much of his study explores Nanotechnology relationship to DNA.
Between 2019 and 2021, his most popular works were:
- Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein. (47 citations)
- Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction (23 citations)
- DNA-directed nanofabrication of high-performance carbon nanotube field-effect transistors (20 citations)
In his most recent research, the most cited papers focused on:
The scientist’s investigation covers issues in Aptamer, Computational biology, Biological studies, Biosensor and Systems engineering.
The various areas that Zhi Zhu examines in his Aptamer study include Algorithm, Leukemia and Systematic evolution of ligands by exponential enrichment.
His Computational biology research includes elements of DNA nanotechnology and Nucleotide.
Zhi Zhu integrates many fields in his works, including Biological studies, Omics, Disease progress, Cellular heterogeneity, Microfluidics and Cell.
Zhi Zhu performs integrative study on Biosensor and Point-of-care testing.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
